Enspryng Injection, Solution
Product Images NDC 50242-007

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Enspryng (NDC 50242-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Enspryng 01)

This appears to be a statistical report of a clinical trial comparing the efficacy of a drug called ENSPRYNG to a placebo. The data seems to indicate that ENSPRYNG is significantly effective in reducing the risk of relapse in patients. The report includes information on the hazard ratio, proportion relapse-free at 96 weeks, and time to relapse in weeks. The sample sizes are N=23 for the placebo and N=41 for ENSPRYNG.*

FDA Label Image

Figure 2 (Enspryng 02)

This is a statistical report for a medical trial with a drug called ENSPRYNG. The report includes data on the risk reduction of relapse, hazard ratio, and proportion of patients who are relapse-free at Week 96. The results show that the drug is effective in preventing relapse in patients with this medical condition.*

FDA Label Image

Image (Enspryng 03)

FDA Label Image

Figure A (Enspryng 04)

This appears to be a set of instructions or warning labels for a medical device. The text mentions "Activation guards," which may be safety features. There is also a warning not to touch a barrel and a notation about the expiration date of a plunger. However, without more context, it is difficult to determine the exact function or purpose of the device.*

FDA Label Image

Figure B (Enspryng 05)

The text describes a "needle-shield" that is extended and locked, but without any context or further information it is not possible to determine what type of device or instrument it is referring to or how it is used.*

FDA Label Image

Figure C (Enspryng 06)

FDA Label Image

Figure D (Enspryng 07)

FDA Label Image

Figure E (Enspryng 08)

FDA Label Image

Figure F (Enspryng 09)

This is a set of instructions regarding how to inspect a medical device, possibly a syringe, before use. It outlines three steps which are checking the expiration date, ensuring the liquid inside is safe for use, and checking the syringe for damage.*

FDA Label Image

Figure G (Enspryng 10)

FDA Label Image

Figure H (Enspryng 11)

FDA Label Image

Figure I (Enspryng 12)

FDA Label Image

Figure J (Enspryng 13)

FDA Label Image

Figure K (Enspryng 14)

FDA Label Image

Figure L (Enspryng 15)

FDA Label Image

Figure M (Enspryng 16)

FDA Label Image

Figure N (Enspryng 17)

FDA Label Image

Figure O (Enspryng 18)

FDA Label Image

Principal Display Panel (120 mg/mL Syringe Carton)

Enspryng (satralizumab-mwge) is an injection medication that comes in a single-dose prefilled syringe. The medication should be refrigerated at 2°C to 8°C (36°F to 46°F) in its original carton to protect it from light. Freezing and shaking should be avoided. The medication guide enclosed in the package must be given to each patient by the pharmacist. This medication is distributed by Genentech and has the National Drug Code (NDC) 50242-007-01.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.